Finding Time for Stress Relief Increasingly Difficult for Oncologists
Many doctors in oncology are pushing themselves to the extreme, and longer workdays have become a fact of life.
Experts: No Savings From Smaller Cancer Drug Packages
Two researchers have challenged the notion that money can be saved
by packaging medications in sizes that conform more closely to
patient weight and dosing needs.
Feeling Chafed by Cigna's Genetics Policy
Cigna's new policy is an extension of a previous Cigna requirement for the use of certified genetic counselors for breast, ovarian, and colorectal cancer genetic tests.
Patient Longevity Will Be Key Driver in Hematology Market Growth
Incoming generic and biosimilar substitutes for dominant, brandname hematology drugs may lead to less costly treatment, but a lot will depend on the quality and supply of these new products,
A Value Proposal That Will Raise Costs
It seems to be that there is a "minor" disagreement between ASCO and CMS about the approach to address value in cancer care delivery.
Florida Practices Band Together for Strength
Florida Cancer Specialists & Research Institute has honed its merger strategy into a finely tuned regimen that goes from due diligence to planning to implementation and follow-up, all in a period as short as 120 days.
Direct Contracting Is the Key to Bypassing the Payer
contracting, a provider signs an agreement with a
business or membership organization outlining the
care to be provided and the payment scheme,
cutting out the insurer completely.
CMS Puts On Its Poker Face
The saying on Wall Street is "sell in May and go away," but there's no detaching from the cliffhanger that CMS has left in the air.
New Blockbusters Will Offset Generic Price Erosion in Hematology
Hematological practices can expect a slate of new generics to replace long-established brand drugs going off patent, as well as new blockbuster blood therapies that will significantly improve the treatment of some malignancies.
Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD
Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma
Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL
Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS
2 Clarke Drive Cranbury, NJ 08512